Coeptis Therapeutics (NASDAQ:COEP) Issues Quarterly Earnings Results

Coeptis Therapeutics (NASDAQ:COEP) released its earnings results on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01, Zacks reports.

Coeptis Therapeutics Stock Down 2.7 %

Coeptis Therapeutics stock opened at $0.20 on Monday. Coeptis Therapeutics has a twelve month low of $0.17 and a twelve month high of $1.38. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.60 and a current ratio of 1.60. The firm has a market cap of $7.49 million, a PE ratio of -0.38 and a beta of -0.90. The firm’s 50 day moving average price is $0.27 and its two-hundred day moving average price is $0.34.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH downgraded Coeptis Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, June 18th.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.